[SCHEDULE 13G] ANAPTYSBIO, INC SEC Filing

Rhea-AI Filing Summary

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 1,426,893 shares of AnaptysBio, Inc. (ANAB), representing 5.1% of the outstanding common stock. The Schedule 13G discloses shared voting and dispositive power over these shares with no sole voting or dispositive power reported. The filing indicates the securities are held by entities subject to voting control and investment discretion by Millennium and related managers.

The filing includes a Joint Filing Agreement dated September 22, 2025, and certifications that the holdings were not acquired to change or influence control of the issuer. Addresses for the reporting persons and CUSIP 032724106 are provided.

Positive

• Transparent disclosure of a 5.1% stake by established institutional investors
• Joint Filing Agreement and signatures confirming coordinated reporting and compliance

Negative

• Shared voting power indicates influence is dispersed rather than centralized, limiting clarity on decision-making authority
• No detail in the filing about which specific affiliated entities hold the shares or trading intentions

Insights

Securities Analyst

TL;DR: A reported passive 5.1% stake by Millennium/Englander signals a meaningful institutional position without an explicit control intent.

The Schedule 13G shows a disclosed aggregate position of 1,426,893 shares, equal to 5.1% of ANAB, reported as shared voting and dispositive power across Millennium entities and Israel A. Englander. Filing under Schedule 13G typically indicates an investor claims passive intent rather than an activist or control purpose. The disclosure and joint filing agreement provide transparency on ownership structure and reporting responsibility but do not convey changes in corporate governance or new strategic plans. For investors, the development documents a material institutional holder above the 5% reporting threshold, which can affect liquidity and potential block trading dynamics.

Corporate Governance Expert

TL;DR: Ownership crossing the 5% threshold requires disclosure; no indication of control or solicitation is stated.

The filing identifies shared voting and dispositive power rather than sole control, and includes the required certification that the stake was not acquired to influence control. The inclusion of a Joint Filing Agreement and signatures dated September 22, 2025, formalize the coordinated reporting among the parties. Absent additional arrangements or amendments, this Schedule 13G signals compliance with disclosure rules while asserting a non-control posture. Market participants should note the precise 5.1% figure as the crossing point that triggers visibility but not necessarily governance influence.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

AnaptysBio, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

032724106

(CUSIP Number)

09/16/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 032724106

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,426,893.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,426,893.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,426,893.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 032724106

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,426,893.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,426,893.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,426,893.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 032724106

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,426,893.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,426,893.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,426,893.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AnaptysBio, Inc.
(b)	Address of issuer's principal executive offices: 10770 Wateridge Circle, Suite 210, San Diego, California 92121
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 032724106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	09/22/2025

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	09/22/2025

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	09/22/2025

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of September 22, 2025, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

What stake in ANAB did Millennium report?

The filing reports beneficial ownership of 1,426,893 shares, representing 5.1% of AnaptysBio common stock.

Who filed the Schedule 13G for ANAB?

The Schedule 13G was filed by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

Does the filing indicate an intent to control AnaptysBio?

No. The filers certified the securities were not acquired to change or influence control and filed on Schedule 13G, which indicates passive intent under the rules.

What voting and dispositive powers are reported?

The filers report 0 sole voting power, 1,426,893 shared voting power, 0 sole dispositive power, and 1,426,893 shared dispositive power.

When was the Joint Filing Agreement executed?

Exhibit I is a Joint Filing Agreement dated September 22, 2025.